Megan Brooks March 08, 2021 The US Food and Drug Administration (FDA) has approved a new, once-daily oral stimulant medication for treatment of attention deficit hyperactivity disorder (ADHD) in people aged 6 years and older. Azstarys (KemPharm, Inc) combines extended-release serdexmethylphenidate (SDX), KemPharm’s prodrug of dexmethylphenidate (d-MPH), coformulated with immediate-release d-MPH. Following absorption in the gastrointestinal tract, SDX is converted to d-MPH, which...